THERAPY DOSSIER · th-07001d6dde19

Autologous bone marrow-derived mononuclear cells

Biologic · Cell therapy (autologous bone marrow mononuclear cells); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Cell therapy (autologous bone marrow mononuclear cells); not a ChEMBL entity
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02027246 ↗Injury indicationPHASE1withdrawn

Autologous Bone Marrow Mononuclear Cell Therapy for Spinal Cord Injury

Spinal Cord Injury

Enrolment: 0 · Results not recorded

NCT00908856 ↗PHASE1withdrawn

Safety of IV Autologous Mononuclear Cells and Marrow Stromal Cells After Stroke

Stroke

Enrolment: 0 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23928737 ↗2013Reported benefit

Autologous bone marrow mononuclear cells therapy attenuates activated microglial/macrophage response and improves spatial learning after traumatic brain injury.

RatTBIControlled cortical impactSprague-DawleyMaleIntravenous injection2 million cells per kilogram body weight, harvested from th…72 h after injury

Model: Controlled cortical impact traumatic brain injury

Intravenous autologous bone marrow mononuclear cells reduced blood-brain barrier permeability at 96 h, increased apoptosis of activated microglia in the ipsilateral hippocampus and improved Morris water maze probe performance at 4 weeks.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.

Loading the evidence…